Iradimed (NASDAQ:IRMD) Hits New 1-Year High – Time to Buy?

Iradimed Corporation (NASDAQ:IRMD)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $52.94 and last traded at $52.68, with a volume of 3648 shares traded. The stock had previously closed at $52.03.

Wall Street Analyst Weigh In

Separately, Roth Mkm lowered their price target on Iradimed from $65.00 to $60.00 and set a “buy” rating for the company in a report on Friday, August 2nd.

Iradimed Stock Up 0.7 %

The company has a market cap of $670.43 million, a PE ratio of 37.27 and a beta of 0.79. The stock’s 50 day simple moving average is $48.68 and its two-hundred day simple moving average is $45.40.

Iradimed (NASDAQ:IRMD) last issued its earnings results on Thursday, August 1st. The medical equipment provider reported $0.38 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.05. Iradimed had a return on equity of 24.71% and a net margin of 26.83%. The business had revenue of $17.93 million for the quarter, compared to analyst estimates of $17.70 million. During the same period last year, the company posted $0.33 EPS. Analysts forecast that Iradimed Corporation will post 1.41 EPS for the current year.

Hedge Funds Weigh In On Iradimed

Large investors have recently modified their holdings of the company. Copeland Capital Management LLC increased its position in Iradimed by 0.3% during the 3rd quarter. Copeland Capital Management LLC now owns 422,425 shares of the medical equipment provider’s stock worth $21,244,000 after purchasing an additional 1,433 shares in the last quarter. Bares Capital Management Inc. increased its position in shares of Iradimed by 0.7% in the first quarter. Bares Capital Management Inc. now owns 279,000 shares of the medical equipment provider’s stock worth $12,273,000 after acquiring an additional 2,000 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Iradimed by 1.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 218,924 shares of the medical equipment provider’s stock valued at $9,620,000 after acquiring an additional 2,079 shares during the period. Hillsdale Investment Management Inc. lifted its holdings in shares of Iradimed by 8.6% during the 1st quarter. Hillsdale Investment Management Inc. now owns 97,400 shares of the medical equipment provider’s stock valued at $4,285,000 after acquiring an additional 7,680 shares in the last quarter. Finally, Isthmus Partners LLC boosted its position in Iradimed by 1.1% during the 2nd quarter. Isthmus Partners LLC now owns 72,664 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 759 shares during the period. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.